RESUMO
We report a 21-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) showing progressive myoclonus epilepsy (PME), who responded to levetiracetam (LEV) at an initial dose of 1,000 mg/day. The patient developed epilepsy at the age of 10 years, and also showed intellectual regression. Various antiepileptic drugs showed no effects on generalized tonic seizures, tonic-clonic seizures, and myoclonus. Addition of LEV (1,000 mg/day) led to the reduction of myoclonus and tonic-clonic seizures, and improved the EEG and sleep-wake rhythm. He had a better appetite and gain weight. It is suggested that LEV may improve quality of life in patients with DRPLA, in addition to reducing the frequency of epileptic seizures.
Assuntos
Anticonvulsivantes/uso terapêutico , Ritmo Circadiano/efeitos dos fármacos , Epilepsias Mioclônicas Progressivas/tratamento farmacológico , Piracetam/análogos & derivados , Anticonvulsivantes/efeitos adversos , Eletroencefalografia/efeitos dos fármacos , Humanos , Levetiracetam , Masculino , Epilepsias Mioclônicas Progressivas/complicações , Epilepsias Mioclônicas Progressivas/etiologia , Piracetam/efeitos adversos , Piracetam/uso terapêutico , Adulto JovemRESUMO
Carbamazepine often causes drug-induced hyponatremia. Hyponatremia due to carbamazepine may be improved by changing to the same mechanism of action, lacosamide.